Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion type Assertion NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_head.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion description "[Overall, erbB2-positive patients had a significantly lower recurrence-free probability than others, 62% at five years as compared to 83%, and showed a significantly decreased breast cancer survival rate (P = 0.0007).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_provenance.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion evidence source_evidence_literature NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_provenance.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion SIO_000772 11205461 NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_provenance.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion wasDerivedFrom befree-2016 NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_provenance.
- NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_assertion wasGeneratedBy ECO_0000203 NP308388.RABdHN0eU-NYluKVeFxGuTJLCCbt25f9YgZWvemFcHG1M130_provenance.